Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled.
/PRNewswire/ Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, today announced its.
Juniper Biologics: Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, today announced its agreement with Ping-An Shionogi Hong Kong, a group company of Shionogi & Co., Ltd, to license the rights to Ensitrelvir Fumaric Acid ("Ensitrelvir") for Singapore. Juniper Biologics has applied for private patient access with the Health Sciences Authority (HSA) of the Republic of Singapore for the indication of SARS-CoV-2 infection.